Buyer clubs and executive access vs the traditional approach: what actually beats what for healthcare and life sciences in emerging markets

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install buyer clubs and executive access has to be shaped to that reality from day one.

The debate about buyer clubs and executive access is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.

Buyer clubs and executive access wins on speed of learning, targeting precision, and cost per outcome. It is curated rooms where the buyer walks in already predisposed to hear you, and it compounds in ways the traditional approach cannot match.

The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first buyer clubs and executive access attempt underperforms — they replace the wrong parts.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Buyer clubs and executive access is only useful here when it is pointed at both constraints at once.

Combine them deliberately. Use buyer clubs and executive access to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.

Metric to watch when running both: cycle length from first touch to closed-won, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.

The failure mode of running both is confusing sponsorship with membership — usually because the traditional team feels threatened and the new model is starved of context.

Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.

Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing buyer clubs and executive access deliberately for this market rather than importing a playbook designed for somewhere else.